Vraylar (cariprazine) is a powerful antipsychotic medication that is approved by the Food and Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD).

Some people experience weight gain during treatment with Vraylar. While exercise may be helpful, it’s crucial not to overheat or dehydrate. Taking Vraylar can affect your metabolism, such as ...

Vraylar (cariprazine) is a prescription drug that helps treat certain mental health conditions. The drug comes as an oral capsule. Vraylar may not be safe to take while pregnant or breastfeeding. Keep ...

It’s not known whether Vraylar is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you should ...

Many people with major depressive disorder don’t get enough relief from their symptoms despite antidepressant medication. To potentially rectify the problem, the U.S. Food and Drug Administration (FDA ...

A patient with depression says she was "stuck" until AbbVie's Vraylar gave her "a lift," which is the theme of the company's latest ad campaign for the mental health drug. Vraylar, a sales blockbuster ...

AbbVie’s new $8.7 billion buyout of psychiatric biotech Cerevel sees it gain a key midstage pipeline med in emraclidine, and the pharma says it will lean on its marketing work for its atypical ...

The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy. The Food and Drug ...

They worked together before on bipolar medication Vraylar, and now Allergan—ahem, AbbVie—will try to repeat that success with Gedeon Richter. AbbVie, which of course absorbed Allergan two years ago, ...

- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant ...

VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022. Following the positive recommendation from INESSS issued in October 2022, VRAYLAR ...